Fundraising Fox
/Companies
Sign in

Acepodia

Founded 2016 · 61 employees on LinkedIn · 2 known investors

Find your way into Acepodia

Sign up to see every warm intro you have to Acepodia

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Acepodia team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Acepodia develops cell therapies for cancer treatment, leveraging proprietary immune cell engineering and tumor-targeting technology to create off-the-shelf therapeutic options for broad patient populations.

BiotechHealthtechMedical Devices

Founders & leadership

Acepodia was founded in 2016 by Patrick Y. Yang and Sonny Hsiao.

PYPatrick Y. Yang
Patrick Y. YangCo-founder, former EVP of Juno Therapeutics, Roche and GenentechPatrick Y. Yang is co-founder of Acepodia and formerly served as Executive Vice President at Juno Therapeutics, as well as holding roles at Roche and Genentech. He has expertise in biotech process research, development, manufacturing, and supply chain across operations in the U.S., Asia/Pacific, and Europe.
SH
Sonny HsiaoCo-founder, UC Berkeley cell biologist

Investors · 2

Also in the syndicate · 1

Digital Mobile Venturelead

Funding

SEC filings, press & company announcements

$209M disclosed across 2 of 3 rounds · 2021–2023

  • $100MSeries DJun 2023 · 2 sources

    Digital Mobile Venture (lead)

    Source ↗
  • $109MSeries CDec 2021 · 2 sources
    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effector Therapies - BioSpacebiospace.com · Dec 2021Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effector Therapiesglobenewswire.com · Dec 2021

Frequently asked questions

What does Acepodia do?
Acepodia develops cell therapies for cancer treatment, leveraging proprietary immune cell engineering and tumor-targeting technology to create off-the-shelf therapeutic options for broad patient populations.
Who founded Acepodia?
Acepodia was founded by Patrick Y. Yang, Sonny Hsiao in 2016.
Who are Acepodia's investors?
Acepodia's investors include Maxpro Ventures.
How much funding has Acepodia raised?
Acepodia has disclosed $209M raised across 2 of its 3 known rounds.